Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

21. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of treatment with donepezil for patients with mild or moderate Alzheimer's disease compared with no drug treatment. The authors concluded that donepezil was cost-effective for patients with mild Alzheimer's disease in Spain. The methods and reporting of the study were adequate and the authors’ conclusions appear

2009 NHS Economic Evaluation Database.

22. Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease

Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Article Text Therapeutics Donepezil is no more effective than placebo for agitation in people

2008 Evidence-Based Mental Health

23. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review

The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

24. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE CRD (...) summary This review concluded that cholinesterase inhibitors (donepezil, galantamine and rivastigmine) were able to stabilise or slow decline in cognition, function, behaviour and global change when compared with placebo. There was no clear evidence to determine whether one of these drugs was more efficacious than another. The review was generally well conducted and the conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety of cholinesterase inhibitors (donepezil

2008 DARE.

25. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Full Text available with Trip Pro

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Fuh J L, Wang S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of donepezil compared with usual care for the treatment of patients with Alzheimer’s disease. The authors concluded that the use of donepezil in Taiwanese patients was potentially cost-effective, and was also cost-saving from a societal perspective. The study methodology seems robust but the sources used to populate the decision model were

2008 NHS Economic Evaluation Database.

26. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL (Abstract)

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular dementia are difficult because of heterogeneous disease mechanisms and overlap between vascular and Alzheimer's disease (AD) pathology in the age-group recruited. Cerebral autosomal dominant arteriopathy with subcortical infarcts (...) and leucoencephalopathy (CADASIL) is a genetic form of subcortical ischaemic vascular dementia. It represents a homogeneous disease process, and because of CADASIL's early onset, comorbid AD pathology is rare. We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL.168 patients with CADASIL (mean age 54.8 years) were assigned to 10 mg donepezil per day (n=86) or placebo (n

2008 EvidenceUpdates Controlled trial quality: predicted high

27. Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long te Full Text available with Trip Pro

Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long te Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long term | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long term

2007 Evidence-Based Mental Health

28. Donepezil for the treatment of agitation in Alzheimer's disease. Full Text available with Trip Pro

Donepezil for the treatment of agitation in Alzheimer's disease. Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 (...) patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks.There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval

2007 NEJM Controlled trial quality: predicted high

29. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Teipel S J, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study determined the cost-effectiveness of donepezil, compared with current care (placebo), for the treatment of Alzheimer's disease in the German setting. The authors concluded that donepezil was a potentially cost-effective alternative to placebo, although the results were highly dependent on the assumptions about treatment effectiveness and remuneration of care-giving

2007 NHS Economic Evaluation Database.

30. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Weycker D, Taneja C, Edelsberg J, Erder M H, Schmitt F A, Setyawan J, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of adjuvant memantine in patients with moderate-to-severe Alzheimer’s disease, who were receiving stable doses of donepezil. The authors concluded that memantine plus donepezil improved the clinical outcomes and reduced the total costs of care

2007 NHS Economic Evaluation Database.

31. Donepezil for mild cognitive impairment. (Abstract)

cognitive deficits and some who may actually improve. Treatment in the very earliest stages of AD may delay progression to AD. Donepezil (Aricept, E2020), a cholinesterase inhibitor, has been shown to benefit all severities of AD including mild and it would be reasonable to investigate its efficacy for those with MCI.To assess the effects of donepezil in people with mild cognitive impairment but no diagnosis of dementia.The trials were identified from a search of the Specialized Register of the Cochrane (...) Donepezil for mild cognitive impairment. Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or diagnostic criteria for MCI, and MCI remains a vague term and those so described are a heterogeneous population, consisting of people who may rapidly progress to dementia but also of people with stable

2006 Cochrane

32. Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Full Text available with Trip Pro

Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Article Text Therapeutics Review: donepezil improves cognitive

2006 Evidence-Based Mental Health

33. Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Full Text available with Trip Pro

Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Article Text

2006 Evidence-Based Medicine

34. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. (Abstract)

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living.We did a 6-month, double-blind, parallel-group (...) , placebo-controlled study in 248 patients with severe Alzheimer's disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer's Disease Cooperative Study activities of daily living

2006 Lancet Controlled trial quality: predicted high

35. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2006; 10(1): 1-176 Authors' objectives The objective of this review was to provide an update review of the best quality evidence for the clinical effectiveness and cost

2006 Health Technology Assessment (HTA) Database.

36. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 111. 2006 Authors' objectives This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately

2006 Health Technology Assessment (HTA) Database.

37. Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease

Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease

2006 Evidence-Based Mental Health

38. Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Full Text available with Trip Pro

Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Article Text

2005 Evidence-Based Mental Health

39. Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Full Text available with Trip Pro

Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Article Text Therapeutics Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Free James Warner

2005 Evidence-Based Mental Health

40. Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Full Text available with Trip Pro

Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Article Text Therapeutics Memantine plus donepezil improves physical and mental health in people

2005 Evidence-Based Mental Health